Nine-month clinical outcomes in patients with stable CAD on s hort vs long DAPT
| Variable | All patients | Less or equal to 6 months of DAPT | Longer than 6 months of DAPT | p Value long vs short DAPT |
| No of patients | 1566 | 384 | 1182 | – |
| 9-month MACE, n (%) | 50 (3.2) | 12 (3.1) | 38 (3.2) | 0.931 |
| 9-month TLR (re-PCI, CABG), n (%) | 33 (2.1) | 8 (2.1) | 25 (2.1) | 0.970 |
| 9-month MI, n (%) | 17 (1.1) | 4 (1.0) | 13 (1.1) | 0.924 |
| 9-month death all causes, n (%) | 14 (0.9) | 4 (1.0) | 10 (0.8) | 0.723 |
| 9-month accumulated definite/probable stent thrombosis, n (%) | 9 (0.6) | 3 (0.8) | 6 (0.5) | 0.538 |
CABG, coronary artery bypass grafting; CAD, coronary artery disease; DAPT, dual-antiplatelet therapy; MACE, major adverse cardiac events; MI, myocardial infarction; re-PCI, re-percutaneous coronary intervention; TLR, target lesion revascularisation.